Literature DB >> 7911380

Rapid detection of loss of heterozygosity of chromosome 17p by polymerase chain reaction-based variable number of tandem repeat analysis and detection of single-strand conformation polymorphism of intragenic p53 polymorphisms.

B Dockhorn-Dworniczak1, C Poremba, R Dantcheva, A Stücker, E Brömmelkamp, S Blasius, W Mellin, A Roessner, D W Yandell, W Böcker.   

Abstract

Intragenic restriction site polymorphisms in amino acid residue 72 in exon 4 and a Mspl polymorphism in intron 6 of the p53 tumour suppressor gene can both serve as polymorphic markers. Probe YNZ22 (D17S5) is a highly polymorphic, variable number of tandem repeat (VNTR) marker which maps to chromosome 17p13.1 where the p53 gene is located. Locus specific amplification by polymerase chain reaction (PCR) technique and subsequent non-isotopic single-strand conformation polymorphism analysis of the PCR fragments was used for the detection of loss heterozygosity (LOH) of 17p including the p53 gene locus. In combination with a PCR-based method for the analysis of the VNTR locus D17S5 using unique sequences flanking the polymorphic region of YNZ22 we investigated tumour DNA and corresponding constitutional DNA from 69 patients, including 39 patients with gastric cancer, 21 patients with osteosarcomas and 9 patients with Ewing's sarcomas. Using all three methods, 49/69 (71%) patients were informative for LOH, which revealed allelic loss in 5/39 (12.8%) gastric cancers, 1/9 (11.1%) Ewing's sarcoma, and 4/20 (20%) osteosarcomas.

Entities:  

Mesh:

Year:  1994        PMID: 7911380     DOI: 10.1007/bf00190553

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  48 in total

1.  Nonisotopic SSCP detection in PCR products by ethidium bromide staining.

Authors:  E P Yap; J O McGee
Journal:  Trends Genet       Date:  1992-02       Impact factor: 11.639

2.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.

Authors:  P Hinds; C Finlay; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

4.  Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis.

Authors:  Y Murakami; K Hayashi; T Sekiya
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

Review 5.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

6.  Retinoblastoma: a prototypic hereditary neoplasm.

Authors:  A G Knudson
Journal:  Semin Oncol       Date:  1978-03       Impact factor: 4.929

7.  Frequency and structure of p53 rearrangements in human osteosarcoma.

Authors:  C W Miller; A Aslo; C Tsay; D Slamon; K Ishizaki; J Toguchida; T Yamamuro; B Lampkin; H P Koeffler
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

8.  The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products.

Authors:  T McDaniel; D Carbone; T Takahashi; P Chumakov; E H Chang; K F Pirollo; J Yin; Y Huang; S J Meltzer
Journal:  Nucleic Acids Res       Date:  1991-09-11       Impact factor: 16.971

9.  Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.

Authors:  S Mashiyama; Y Murakami; T Yoshimoto; T Sekiya; K Hayashi
Journal:  Oncogene       Date:  1991-08       Impact factor: 9.867

10.  Human breast cancer: frequent p53 allele loss and protein overexpression.

Authors:  S Singh; M Simon; I Meybohm; I Jantke; W Jonat; H Maass; H W Goedde
Journal:  Hum Genet       Date:  1993-02       Impact factor: 4.132

View more
  5 in total

1.  High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping.

Authors:  Daniel A Peiffer; Jennie M Le; Frank J Steemers; Weihua Chang; Tony Jenniges; Francisco Garcia; Kirt Haden; Jiangzhen Li; Chad A Shaw; John Belmont; Sau Wai Cheung; Richard M Shen; David L Barker; Kevin L Gunderson
Journal:  Genome Res       Date:  2006-08-09       Impact factor: 9.043

2.  p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.

Authors:  R Schneider-Stock; K Radig; Y Oda; W Mellin; J Rys; A Niezabitowski; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions.

Authors:  Jingcui Yu; Peng Liu; Xiaobo Cui; Yu Sui; Guohua Ji; Rongwei Guan; Donglin Sun; Wei Ji; Fangli Liu; An Liu; Yuzhen Zhao; Yang Yu; Yan Jin; Jing Bai; Jingshu Geng; Yingwei Xue; Jiping Qi; Ki-Young Lee; Songbin Fu
Journal:  Mol Cells       Date:  2011-04-20       Impact factor: 5.034

4.  [The demonstration of the radiation-induced production of tumor necrosis factor-alpha in Ewing's sarcoma RM 82 in vitro and in vivo].

Authors:  C Rübe; C Finke; F van Valen; K L Schäfer; B Dockhorn-Dworniczak; N Willich
Journal:  Strahlenther Onkol       Date:  1997-08       Impact factor: 3.621

5.  Frequency and spectrum of p53 mutations in gastric cancer--a molecular genetic and immunohistochemical study.

Authors:  C Poremba; D W Yandell; Q Huang; J B Little; W Mellin; K W Schmid; W Böcker; B Dockhorn-Dworniczak
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.